!["I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/11e93c561a9ff98f731b152d7f48e6f792831864-1000x1000.jpg?w=350&fit=crop&auto=format)
|Articles|June 24, 2010
2010 Hema intro
Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan
Advertisement
Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
3
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
4
Balancing Oncologic Outcomes With Patient Priorities in Prostate Cancer Care
5






















































